Serum antibodies to 25 myelin oligodendrocyte glycoprotein epitopes in multiple sclerosis and neuromyelitis optica: clinical value for diagnosis and disease activity.
- Author:
Yan XU
1
;
Yao ZHANG
;
Cai-yan LIU
;
Bin PENG
;
Jian-ming WANG
;
Xiao-jun ZHANG
;
Hai-feng LI
;
Li-ying CUI
Author Information
- Publication Type:Journal Article
- MeSH: Adult; Antibodies; blood; immunology; Epitopes; immunology; Female; Humans; Male; Middle Aged; Multiple Sclerosis; blood; immunology; Myelin-Oligodendrocyte Glycoprotein; immunology; Neuromyelitis Optica; blood; immunology
- From: Chinese Medical Journal 2012;125(18):3207-3210
- CountryChina
- Language:English
-
Abstract:
BACKGROUNDWhether antibody to myelin oligodendrocyte glycoprotein (MOG) can be a diagnostic marker for multiple sclerosis (MS) is still controversial. Recent studies suggested that serum specific anti-MOG epitope antibody might be an MS specific marker. However, these studies did not include neuromyelitis optica (NMO) which might be proven to also have anti-MOG antibody. Hence, the present study was undertaken to investigate the clinical value of serum antibodies to 25 MOG epitopes in conventional MS (CMS) and NMO.
METHODSSerum anti-MOG epitope IgG was detected in 61 CMS patients, 54 NMO patients, and 77 healthy controls, using enzyme-linked immunosorbent assay (ELISA).
RESULTSAnti-MOG(27-38) IgG levels in both CMS and NMO patients were significantly higher than that in healthy controls (optical density (OD): 0.64 ± 0.38, 0.48 ± 0.23 vs. 0.19 ± 0.09; P = 0.000). CMS and NMO patients in relapse stage had significantly higher anti-MOG(27-38) IgG level than patients in remission stage (OD: 0.55 ± 0.14 vs. 0.24 ± 0.09, P = 0.027).
CONCLUSIONAlthough serum anti-MOG epitope IgG could not differentiate MS from NMO, it may be a useful marker for monitoring disease activity.
